<DOC>
	<DOCNO>NCT01421875</DOCNO>
	<brief_summary>RATIONALE : Studying blood sample patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research trial study biomarkers related chemotherapy resistance outcome sample old patient acute myeloid leukemia .</brief_summary>
	<brief_title>Biomarker Study Chemotherapy Resistance Outcomes Samples From Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Delineate spectrum genetic epigenetic lesion occur elderly patient acute myeloid leukemia ( AML ) . - Determine biological function perturb lesion . - Identify validate lesion pathways highly associate chemo-sensitive chemo-refractory disease , adverse outcome elderly AML . - Identify potential classifier biomarker lesion evaluate prospectively E2906 trial begin enrollment . OUTLINE : DNA RNA extract cell sample analyze genetic epigenetic expression Agilent SureSelect sequencing , Illumina HiSeq2000 platform cod sequencing , DNA methylation , microarray assay . Results associate patient ' overall survival , progression-free survival , complete response rate . Results also analyze assess prognostic relevance know mutation epigenetic alteration show impact overall survival response therapy young patient acute myeloid leukemia ( AML ) E1900 include , limited , FLT3 , DNMT3A , IDH1 , IDH2 , TET2 , ASXL1 , WT1 , MLL , 15-gene DNA methylation classifier , novel recurrent mutation identify AML-profiling effort .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Subset patient diagnose acute myeloid leukemia ( AML ) enrol E3999 AML resistant sensitive chemotherapy Mononuclear cell sample available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>